Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BMS-986258 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
BMS-986258 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
CC-90002 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
CC-90002 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
CC-115 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
CC-115 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Cabiralizumab by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval
Cabiralizumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer. According to...
Cabiralizumab by Bristol-Myers Squibb for Glioblastoma Multiforme (GBM): Likelihood of Approval
Cabiralizumab is under clinical development by Bristol-Myers Squibb and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...
BMS-986360 by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval
BMS-986360 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
BMS-986360 by Bristol-Myers Squibb for Sarcomas: Likelihood of Approval
BMS-986360 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Sarcomas. According to GlobalData, Phase I...
Adakitug by Bristol-Myers Squibb for Renal Cell Carcinoma: Likelihood of Approval
Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase I for Renal Cell Carcinoma. According to GlobalData,...
Mocetinostat by Bristol-Myers Squibb for Rhabdomyosarcoma: Likelihood of Approval
Mocetinostat is under clinical development by Bristol-Myers Squibb and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I...
Mocetinostat by Bristol-Myers Squibb for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
Mocetinostat is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
DF-1001 by Bristol-Myers Squibb for Colorectal Cancer: Likelihood of Approval
DF-1001 is under clinical development by Bristol-Myers Squibb and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
Nivolumab by Bristol-Myers Squibb for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Carcinoma. According to...
Nivolumab by Bristol-Myers Squibb for Merkel Cell Carcinoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...
Nivolumab by Bristol-Myers Squibb for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According...
Nivolumab by Bristol-Myers Squibb for Basal Cell Carcinoma (Basal Cell Epithelioma): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma)....
Nivolumab by Bristol-Myers Squibb for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to...
Nivolumab by Bristol-Myers Squibb for Skin Cancer: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Skin Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Danicamtiv?
Danicamtiv is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase II program in Systolic Heart Failure. According...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's BMS-986012?
BMS-986012 is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Small-Cell Lung Cancer. According...
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Milvexian?
Milvexian is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Atrial Flutter. According to...